Horizon Therapeutics NASDAQ HZNP
$116.30 0.0000 0.0000%
Today share price
Ireland
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 38 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

27.21B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

27.42B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

1.04
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

233.94M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-
Upcoming events Horizon Therapeutics All events
No upcoming events scheduled

Stock chart Horizon Therapeutics

Stock analysis Horizon Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
62.12 -88.70
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
5.36 12.53
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
30.38 -27.79
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.23 0.63
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
8.25 -1.16

Price change Horizon Therapeutics per year

66.41$ 115.86$
Min Max

Summary analysis Horizon Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Horizon Therapeutics

Revenue and net income Horizon Therapeutics

All parameters
Stock news Horizon Therapeutics All news

Third Harmonic Bio Taps Horizon Therapeutics Alum for Finance Chief

Third Harmonic Bio Taps Horizon Therapeutics Alum for Finance Chief

Amgen to Lay Off 350 U.S. Employees of Horizon Therapeutics

Amgen to Lay Off 350 U.S. Employees of Horizon Therapeutics

FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics

FTC Settles With Amgen Over $27.8 Billion Deal for Horizon Therapeutics

Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen

S&P 500 Futures Up in Premarket Trading; VinFast Auto, Horizon Therapeutics Lead

FTC Pauses Challenge to Amgen’s $27.8 Billion Deal for Horizon Therapeutics

Horizon Therapeutics Sees Positive Results in Tepezza Trial for Treatment of Thyroid Eye Disease

Horizon Therapeutics Sees Positive Results in Tepezza Trial for Treatment of Thyroid Eye Disease

FTC sues to block Amgen’s acquisition of Horizon Therapeutics

FTC Poised to Block Amgen’s $27.8 Billion Deal for Horizon Therapeutics

S&P 500 Futures Decline in Premarket Trading; Horizon Therapeutics, agilon health Lag

Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal

Horizon Therapeutics Stock Plunges on Reports FTC Will Sue to Block Amgen Deal

Home Depot, Capital One, Horizon Therapeutics, Baidu, Vodafone, and More Stock Market Movers

Home Depot, Capital One, Horizon Therapeutics, Baidu, Vodafone, and More Stock Market Movers

Amgen plans mega bond deal to help fund $28 billion Horizon Therapeutics acquisition

Amgen plans mega bond deal to help fund $28 billion Horizon Therapeutics acquisition

About company Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Address:
Connaught House, Dublin, Ireland, 4
Company name: Horizon Therapeutics
Issuer ticker: HZNP
ISIN: IE00BQPVQZ61
Country: Ireland
Exchange: NASDAQ
Currency: $
IPO date: 2011-07-28
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.horizontherapeutics.com

On which stock exchange are Horizon Therapeutics (HZNP) stocks traded?

Horizon Therapeutics (HZNP) stocks are traded on NASDAQ.

What is the ticker of Horizon Therapeutics stocks (HZNP)?

The stock ticker of Horizon Therapeutics’s stocks or in other words, the code is HZNP. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Horizon Therapeutics (HZNP) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Horizon Therapeutics (HZNP) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Horizon Therapeutics (HZNP) stocks traded?

Horizon Therapeutics (HZNP) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Horizon Therapeutics (HZNP) stocks today?

The current price of Horizon Therapeutics stocks on 29.03.2024 is 116.3 dollars. per share.

What is the dynamics of Horizon Therapeutics (HZNP) stocks from the beginning of the year?

Horizon Therapeutics (HZNP) quotes have increased by 0% from the beginning of the year up to 116.3 dollars. per 1 stocks.

How much did Horizon Therapeutics (HZNP) stocks increase in марте 2024?

This month Horizon Therapeutics (HZNP) quotes have increased by 0% to 116.3 dollars. per share.

How much are Horizon Therapeutics (HZNP) stocks worth?

Today, on October, 29.03.2024 Horizon Therapeutics’s (HZNP) stocks cost 116.3 dollars..

What is the market capitalization of Horizon Therapeutics (HZNP)?

Capitalization is the market value of Horizon Therapeutics (HZNP) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 29.03.2024, the market capitalization of Horizon Therapeutics (HZNP) is estimated at about 27206709233 dollars.